These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19740488)

  • 41. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Genetics and present therapy options in Parkinson's disease: a review].
    Bereznai B; Molnar MJ
    Ideggyogy Sz; 2009 May; 62(5-6):155-63. PubMed ID: 19579663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mutation in LRRK2 is associated with familial presentation of Parkinson's disease in a Chilean kindred].
    Miranda M
    Rev Med Chil; 2007 Mar; 135(3):406-7. PubMed ID: 17505590
    [No Abstract]   [Full Text] [Related]  

  • 44. Parkinson's disease.
    Thomas B; Beal MF
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report.
    Wu CK
    Acta Neurol Taiwan; 2011 Mar; 20(1):4-14. PubMed ID: 21560084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dementia in Parkinson's disease.
    Aarsland D; Beyer MK; Kurz MW
    Curr Opin Neurol; 2008 Dec; 21(6):676-82. PubMed ID: 18989112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutations in LRRK2 as a cause of Parkinson's disease.
    Giasson BI; Van Deerlin VM
    Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From genes to proteins in mendelian Parkinson's disease: an overview.
    Pirkevi C; Lesage S; Brice A; Başak AN
    Anat Rec (Hoboken); 2009 Dec; 292(12):1893-901. PubMed ID: 19943343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients.
    Aguiar Pde C; Lessa PS; Godeiro C; Barsottini O; Felício AC; Borges V; Silva SM; Saba RA; Ferraz HB; Moreira-Filho CA; Andrade LA
    Mov Disord; 2008 Jul; 23(9):1228-33. PubMed ID: 18464276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
    Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
    Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
    Spanaki C; Latsoudis H; Plaitakis A
    Neurology; 2006 Oct; 67(8):1518-9. PubMed ID: 17060595
    [No Abstract]   [Full Text] [Related]  

  • 53. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.
    Goris A; Williams-Gray CH; Clark GR; Foltynie T; Lewis SJ; Brown J; Ban M; Spillantini MG; Compston A; Burn DJ; Chinnery PF; Barker RA; Sawcer SJ
    Ann Neurol; 2007 Aug; 62(2):145-53. PubMed ID: 17683088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease.
    De Marco EV; Tarantino P; Rocca FE; Provenzano G; Civitelli D; De Luca V; Annesi F; Carrideo S; Cirò Candiano IC; Romeo N; Nicoletti G; Marconi R; Novellino F; Morelli M; Quattrone A; Annesi G
    Am J Med Genet B Neuropsychiatr Genet; 2008 Apr; 147(3):403-7. PubMed ID: 17918232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic mouse models of Parkinson's disease The state of the art.
    Magen I; Chesselet MF
    Prog Brain Res; 2010; 184():53-87. PubMed ID: 20887870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits.
    Wurtman RJ
    Metabolism; 2013 Jan; 62 Suppl 1():S27-9. PubMed ID: 22999712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new start for Parkinson's disease?
    Siva N
    Lancet Neurol; 2006 Jan; 5(1):24-5. PubMed ID: 16400733
    [No Abstract]   [Full Text] [Related]  

  • 58. Revelations and revolutions in the understanding of Parkinson's disease.
    Dawson TM; Moore DJ; West AB
    Biochim Biophys Acta; 2009 Jul; 1792(7):585-6. PubMed ID: 19539178
    [No Abstract]   [Full Text] [Related]  

  • 59. The common PARK8 mutation LRRK2G²⁰¹⁹S is not a risk factor for breast cancer in the absence of Parkinson's disease.
    Mortiboys H; Cox A; Brock IW; Bandmann O
    J Neurol; 2013 Aug; 260(8):2177-8. PubMed ID: 23824357
    [No Abstract]   [Full Text] [Related]  

  • 60. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
    Paisán-Ruíz C; Jain S; Evans EW; Gilks WP; Simón J; van der Brug M; López de Munain A; Aparicio S; Gil AM; Khan N; Johnson J; Martinez JR; Nicholl D; Martí Carrera I; Pena AS; de Silva R; Lees A; Martí-Massó JF; Pérez-Tur J; Wood NW; Singleton AB
    Neuron; 2004 Nov; 44(4):595-600. PubMed ID: 15541308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.